Objective: To evaluate netarsudil's role as first-line therapy for the treatment of open-angle
glaucoma (OAG) and ocular hypertension (OHT). Data Sources: A literature search utilizing …

Background: Vision impairment remains a major health problem worldwide. Elevated
intraocular pressure is a prime risk factor for blindness in the elderly. Netarsudil is a Rho …

Objective Assess the real-world efficacy of netarsudil, either as monotherapy or concomitant
therapy, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) …

Purpose: Glaucoma is the second leading cause of blindness worldwide, affecting more
than 64 million people aged 40–80. The best way to manage primary open-angle glaucoma …

Introduction New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that
reduce treatment burden and improve outcomes relative to currently available agents are …

Introduction A clinical trial evaluated ocular hypotensive efficacy and safety of netarsudil
0.02% once daily (QD) relative to ripasudil 0.4% twice daily (BID). Methods This was a …

Purpose To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02%
ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in …

Purpose To evaluate the effectiveness of netarsudil in combination with other ocular
hypotensive agents in patients with open-angle glaucoma (OAG) or ocular hypertension …

Purpose To evaluate the efficacy and safety profile of netarsudil 0.02% ophthalmic solution
in a tertiary glaucoma referral center. Methods This retrospective cohort study included …

Introduction Netarsudil reduces intraocular pressure (IOP) by increasing aqueous outflow
through the trabecular meshwork (TM) pathway and decreasing episcleral venous pressure …